49 results about "Treatment research" patented technology

The invention discloses a drug screening method based on endotoxin attack, and relates to the technical field of drug screening, in the process of drug screening by using an experimental animal, firstly, an experimental animal model with diseases is established, a certain dose of endotoxin is given to the experimental animal for a period of time after the model is successfully built, and then the experimental animal is subjected to drug screening. And establishing evaluation indexes by utilizing a mathematical formula, and comprehensively evaluating the effectiveness and the safety of the medicine. The evaluation indexes comprise an endotoxin attack survival rate, a survival disease control rate and a survival disease control index. The method can be applied to screening of drugs for treating different diseases, and a more scientific and reliable screening method is provided for research of preclinical drugs or treatment methods.

The invention discloses an acoustic catalyst as well as a preparation method and application thereof, and belongs to the technical field of catalysts and drug therapy. NJU-319 is selected as an acoustic catalyst, NJU-319Pt is synthesized from a porphyrinyl linker (TAPP) and a hexaphenyl triphenyl unit (HFPTP) under a solvothermal condition, and the H2 generation efficiency of NJU-319Pt can be further improved. After intraperitoneal injection, the nano-drug NJU-319Pt catalyzes H2O to be reduced into H2 under ultrasonic irradiation, and meanwhile lactic acid is oxidized into pyruvic acid. The action mechanism comprises: removing ROS and relieving oxidative stress; by inhibiting an NF-kappa B pathway, the transformation of macrophages from M1 phenotype to M2 phenotype is promoted, and inflammation is reduced; mitochondrial membrane potential is reduced, EMs cell apoptosis is induced, and focus growth is inhibited. The research provides a brand new EMs treatment strategy, combines acoustic catalysis H2 generation with lactic acid oxidation, and provides a new direction for EMs treatment research.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a duochin in preparation of a medicine for treating MASLD. The research finds that the eriochin has a positive effect on treatment of MASLD, and can effectively delay the body weight, liver weight and liver weight-body weight ratio of MASLD mice, relieve liver injury, relieve liver lipid deposition, liver fatty degeneration, inflammation and fibrosis and delay the MASLD disease progress. Research finds that the eriochin can effectively reduce body weight, relieve liver injury and relieve fatty degeneration and inflammation of the liver, so that MASLD is improved. The invention provides a new thought for the treatment research of MASLD.

The invention discloses an STING agonist polypeptide conjugate as well as a composition and application thereof, and belongs to the field of medicinal chemistry, an STING agonist and a straight-chain peptide or a cyclic peptide are directly connected or connected through a linking group, the formed conjugate can target a tumor microenvironment, and the STING agonist is controllably released in specific time and space, so that the tumor microenvironment is inhibited, and the tumor microenvironment is inhibited. Therefore, the drug enrichment amount of the tumor site is increased, the drug treatment efficiency and bioavailability are improved, the toxic and side effects are reduced, and the purposes of effect enhancement and toxicity reduction are achieved. According to the STING agonist polypeptide conjugate, the targeting property of STING agonist drugs on tumor tissues is improved, the toxic and side effects on normal tissues are reduced, the STING agonist polypeptide conjugate is a brand-new immune agonist type coupling drug, and a new scheme is provided for tumor immunotherapy research.

The invention discloses application of a caenorhabditis elegans reproductive disorder model to screening of strains promoting reproduction health, and relates to the technical field of biologica.Cyclophosphamide medicine intervention is applied to caenorhabditis elegans, so that the normal reproductive system of caenorhabditis elegans is damaged, and the reproductive disorder model is prepared; then 3985 gene knockout strains in an escherichia coli Keio gene knockout library are utilized, and strains with the reproductive capacity remarkably improved for reproductive disorder are screened; and carrying out homologous gene knockout on the probiotics by using a gene editing technology, and screening out the probiotics with the potential of promoting reproductive health. The reproductive disorder model is stable and repeatable, can be used for screening strains or drugs for improving the reproductive function, and also can be used for screening candidate strains or drugs for reducing the reproductive toxicity of cyclophosphamide. According to the method, an effective tool is provided for screening of reproduction-related probiotic strains or screening of related drugs, and meanwhile, the strains screened based on the model provide new candidate strains for treatment and research of reproductive disorder diseases.

The invention belongs to the technical field of medical experimental animal models, provides a construction method of a dry age-related macular degeneration animal model, and aims to break through the technical bottlenecks of long construction period, high cost and incomplete pathological feature coverage of an existing model. D-galactose is used for inducing glycosylation end product accumulation and mitochondrial dysfunction, oxidative stress, RPE metabolic disorder and inflammation microenvironment in the dry AMD pathogenesis process can be synchronously simulated, core pathological characteristics such as retina glass membrane wart deposition, RPE atrophy, retina and visual function damage and the like can be accurately reproduced, meanwhile, a multi-dimensional verification system is matched, and the method has the advantages that the method is simple and convenient to operate and high in practicability. The method is suitable for preclinical evaluation of personalized treatment strategies; besides, the method is short in modeling period, the animal model meeting the requirement can be obtained within 8 weeks, the cost advantage is outstanding, and an efficient and reliable experimental animal model can be provided for dry AMD treatment research.

The invention belongs to the technical field of biological medicines, and particularly relates to sulfonium salt polypeptide or protein as well as a preparation method and application thereof. Polypeptide or protein containing cysteine and a sulfonium salt compound are used as raw materials, and the sulfonium salt compound is used for alkylation of cysteine at a specific site of the polypeptide or protein to prepare the sulfonium salt polypeptide or protein. The sulfonium salt polypeptide or protein is used as a probe for covalently labeling tryptophan in a lysine methylation reader protein recognition pocket. According to the method disclosed by the invention, different types of sulfonium salt polypeptides and protein probes can be simply, conveniently and efficiently prepared, and the designed annular sulfonium salt with a novel skeleton has an obvious improvement on the polypeptide or protein labeling yield of reader protein. The prepared sulfonium salt probe not only can be used for identifying lysine methylation modified reader protein and finding a therapeutic target for disease-related pathways, but also can be used for modifying tryptophan at a specific site of an antibody-coupled drug and provides a powerful tool for targeted therapy research of tumors.

The invention belongs to the technical field of biological medicines, and particularly relates to application of an SLCO4C1 accelerant in preparation of an anti-MASLD medicine. The SLCO4C1 accelerant comprises a carrier or an adenovirus which is used for overexpressing the SLCO4C1. Research finds that liver specific overexpression SLCO4C1 can effectively reduce body weight, relieve liver injury and relieve fatty degeneration, inflammation and fibrosis of the liver, so that MASLD is improved. The invention proves that the liver specific overexpression SLCO4C1 has an excellent effect of improving the MASLD, and a new thought is provided for the treatment research of the MASLD.

The invention belongs to the technical field of functional materials, and particularly relates to a preparation method and application of antioxidant carbon dots based on H2O2 diagnosis and treatment. According to the anti-oxidation carbon dot, curcumin and o-phenylenediamine serve as precursors, the anti-oxidation carbon dot with the fluorescence luminescence characteristic is prepared, and high-sensitivity response to H2O2 can be achieved. In an osteoarthritis environment, the carbon dot has a diagnosis and treatment effect by detecting H2O2 concentration change and using a fluorescence signal, and meanwhile, by virtue of the excellent oxidation resistance of the carbon dot, the progress of early joint diseases can be delayed. The carbon dots integrating detection and treatment functions have wide application prospects in the biomedical field, and particularly show important potential in diagnosis and treatment research of oxidative stress related diseases such as osteoarthritis.

This application relates to the technical field of medical research and clinical experiments, and provides an experimental method for clinical research of targeting molecules based on an atrial fibrillation warning system. The method includes: continuously monitoring dynamic electrocardiograms of a patient using an atrial fibrillation warning system; when the atrial fibrillation warning system issues an alert indicating imminent atrial fibrillation, immediately collecting blood or other clinical information of the patient; collecting blood or other clinical information of the patient when the patient has not experienced atrial fibrillation and the atrial fibrillation warning system has not issued an alert, to serve as control data; comparing biological indicators during atrial fibrillation occurrence and non-occurrence, and analyzing potential triggering factors and targeting molecules; and based on the identified targeting molecules, conducting targeted treatment research to validate effectiveness of the targeting molecules.

The invention discloses an AML chemotherapy regimen sharing method and system based on distributed processing, and belongs to the technical field of medical information. The method comprises the following steps: acquiring clinical data related to an AML chemotherapy regimen, including patient information, pathological indexes and iconography data, performing preprocessing and semantic annotation, and generating a semantic clinical data unit with a distributed identifier; registering the identifier, the metadata and the digital signature to a distributed account book network maintained by multiple mechanisms; receiving a query request based on the semantic tag and the metadata, and matching a data unit in an account book network through a semantic engine; and after verifying the authority of the requester, transmitting a data load or executing a distributed computing task of which the data cannot be out of the domain through the secure channel. The problems of privacy security, cross-mechanism interoperation and credible authentication in clinical data sharing are effectively solved, and an efficient and reliable data collaboration platform is provided for AML diagnosis and treatment research.

The invention discloses application of a mutant gene related to ASD, the mutant gene is at least one of the following genes: RAB5A, EFNB2, NEDD9, WNT9B, LIN7C, FOLR1, BNIP3, CAMSAP2, ADCY10, FCSK, UGDH and PIGH, the genes are related to ASD phenotype related pathways, but the genes are not recorded in an SFARI / HPO database before. The findings are beneficial to clarification of genetic causes of ASD and provide favorable help for early diagnosis and treatment research of ASD.

The invention belongs to the technical field of tumor molecular biology, and discloses a digestive tract tumor cross-cancer-species molecular typing method and application thereof. According to the method, six-dimensional molecular characteristics are integrated by using a robust rank polymerization algorithm, and high-confidence functional genes are screened through RNAi and CRISPR dual verification, so that the problems of single dimension and insufficient specificity of traditional screening are solved, the functional gene screening is more accurate, and a reliable foundation is laid for typing; the method has the advantages that tissue origin limitation is broken through, unified typing of the generic gastrointestinal tumors is realized, stability is verified in multi-queue and multi-technical platform samples by determining four types of subtypes, stability and unification of cross-cancer type typing are realized, and a new standardized diagnosis and treatment thought is provided. The molecular subtype determined by the method is used for in-vitro drug response prediction for non-diagnosis / treatment purposes, a scientific basis is provided for risk stratification and individualized medication research, precise treatment research is further promoted, and clinical guidance value is outstanding.

The invention discloses a traditional Chinese medicine accurate diagnosis and treatment research platform for endometriosis. The traditional Chinese medicine accurate diagnosis and treatment research platform comprises a cross-mechanism data collaboration interface, a distributed feature extraction engine module and a multi-mode classification decision module, the cross-mechanism data collaboration interface is used for realizing standardized data interaction with an external mechanism; the distributed feature extraction engine module is used for sending the metadata request to an external mechanism and analyzing metadata information returned by the external mechanism; the multi-modal classification decision module is used for classifying analyzed results; the method is characterized in that the metadata request at least comprises the following steps: inputting a data modal specification; the metadata information at least comprises input data modal specifications and all pathological feature data. On the basis of protecting customer privacy, data sharing between external institutions such as hospitals, clinics and research institutions and the system is achieved, so that richer pathological research information is obtained.

The invention discloses a novel anti-tumor two-dimensional photothermal material and a preparation method thereof.The preparation method comprises the steps that after a BP nanosheet is prepared through a liquid stripping technology, Fe < 3 + > is introduced, FeBPs is prepared through an in-situ biomimetic mineralization method, BP is subjected to in-situ biomimetic mineralization through metal ions Fe < 3 + >, and the black phosphorus nanosheet-(FeBPs) with the surface modified by an iron-phosphoric acid organic coordination layer is constructed. After the FeBPs enter tumor cells, dissociation of a mineralization layer is initiated under the synergistic effect of GSH, Fe < 3 + > is reduced into Fe < 2 + >, a large amount of GSH in the cells is consumed, the GPX4 protein level is lowered, ROS accumulation is caused, and tumor cell ferroptosis is induced. Meanwhile, by means of the excellent photo-thermal performance of BP after dissociation of the mineralization layer, under irradiation of near-infrared light 808 nm, the temperature of tumor tissue is increased, tumor ablation is caused, then photo-thermal / ferroptosis collaborative treatment is achieved, and a new treatment strategy is provided for tumor treatment research.

The invention belongs to the technical field of compounds, and provides a croconoic acid bisindole compound and a preparation method and application thereof. The croconoic acid bisindole compound with a specific structure provided by the invention contains a croconoic acid group, an indole group and a morpholine group in the structure. The croconoic acid group makes the compound structure more stable and also has longer ultraviolet absorption. The indole group gives the compound pH value response, and the morpholine group has a good lysosome targeting mechanism. The croconoic acid bisindole compound provided by the invention has the characteristics of lysosome targeting, pH value responsiveness, near-infrared-photoacoustic dual-modality imaging, and photothermal therapy, and has small toxic and side effects, and can be used for imaging and treatment research of tumors, especially breast cancer cells.

The present invention discloses an application of APP in non-alcoholic fatty hepatitis, specifically including the application of APP in the preparation of NASH detection reagents and the application of APP in the preparation of NASH therapeutic drugs. Changes in APP expression have a regulatory effect on NASH. If the therapeutic drug contains an APP small interfering siRNA sequence, the expression of APP in the liver can be downregulated, and the fatty changes in the liver of NASH can be alleviated. The present invention also discloses a method for constructing a NASH animal model, in which the APP gene is knocked out, and it is intended to solve and make up for the deficiencies of the existing technology in the detection and treatment research of the occurrence and development of NASH and the role and evaluation method of APP. The present invention provides a research method and application of APP in NASH, which is convenient for in-depth analysis of the role of APP in NASH. At the same time, the application of this technical solution facilitates the elucidation of the mechanism of action of APP and provides a new perspective for the study of APP.

The present invention provides a nano - monoclonal antibody IDM2 - 27 targeting HER2, its preparation method and applications. The complementarity - determining regions (CDRs) of the nano - monoclonal antibody include CDR1, CDR2 and CDR3. Among them, the amino acid sequences of CDR1, CDR2 and CDR3 are GFTFSSYS, INSDGSST and GKGGLHYSDYE respectively. The nano - monoclonal antibody provided by the present invention has high specificity for human HER2 protein, strong affinity, is easy to produce and has high stability, and is suitable for various cancer diagnosis and treatment research targeting HER2.

This invention provides a dual-target nucleic acid aptamer, conjugate, preparation method, and application. Using Nectin4 and c-Met as dual targets, this invention designs and constructs a dual-target nucleic acid aptamer-MMAE conjugate. Stable conjugation between the nucleic acid aptamer and MMAE is achieved through a maleimide-thiol specific reaction. Through systematic structural characterization, in vitro functional verification, and in vivo imaging and therapeutic studies, the invention verifies the conjugate's targeting ability for bladder cancer, in vitro antitumor activity, and in vivo tumor enrichment and growth inhibition effects. This addresses the problem of insufficient MMAE targeting, providing a new experimental model and theoretical basis for nucleic acid aptamer-mediated targeted delivery of small molecule cytotoxic drugs, and exploring new strategies for dual-target precision treatment of bladder cancer.

The present invention provides a fixing device for experimental animals and a magnetic resonance examination device, relating to the field of experimental examination devices, and solving the problem that there is a lack of supporting equipment for animal experiments of magnetic wave knives in the current market. The fixing device for experimental animals includes: an examination bed; a first fixing device fixed on the examination bed for fixing the body of the experimental animal; a second fixing device, a third fixing device and a fourth fixing device fixed on the examination bed for fixing the head of the experimental animal, wherein the second fixing device is fixedly connected to the first fixing device; the third fixing device is fixed on the examination bed and fixedly connected to the fourth fixing device; wherein, the third fixing device is an open container, and the head of the experimental animal is placed on the opening of the open container; the fourth fixing device is a fixing bracket for fixing the two ear parts of the head of the experimental animal. The solution of the present invention realizes the treatment research of experimental animals in the field of magnetic wave knives.

The invention provides a primate-based intelligent noninvasive brain pacemaker performance and effectiveness verification method and system, and the method and system show significant advantages in the aspects of technology, economy and experimental ethics. According to the method, high space-time resolution source imaging combining high-density EEG and magnetic resonance imaging (MR I) is adopted, the system can accurately capture TES-induced neural oscillation changes (the time resolution is 1ms) through a millisecond-level dynamic response correlation technology, and the spatial positioning accuracy smaller than or equal to 2mm is achieved in a Parkinson disease macaque model. In addition, long-term dynamic research as long as 6 months is supported, a reliable basis is provided for clinical transformation, and it is predicted that the clinical test failure rate can be reduced by 20%. The method not only accords with the '3R principle 'of animal experiments, but also provides an innovative platform with scientific value and social benefit for brain disease treatment research through non-invasive, high-precision and multi-dimensional technical breakthrough.

The invention belongs to the technical field of biological medicines, and particularly relates to a culicoides streptonicoides allergen as well as an identification method, an antibody and application thereof. The culicoides chromogen is maltase Cel t 1, and the amino acid sequence of the maltase Cel t 1 is as shown in SEQ NO. 1. According to the application disclosed by the invention, the maltase Curet 1 obtained by screening is used as the culicoides chromogen, so that the defect of single research object of blood-sucking midges in the early stage can be overcome, and a good foundation is laid for subsequent blood-sucking midge chromogen research. Meanwhile, one of sensitizers in the culicoides is defined on the basis of the culicoides-mouse sensitization model constructed through early-stage research, an efficient technical method is provided for research on identification of the culicoides sensitizers, and meanwhile basic data is provided for subsequent vaccine prevention and treatment research.

This application relates to the fields of biomedical engineering and neuromodulation, disclosing the application of ultrashortwave in the fabrication of devices for modulating brain neural activity. The modulation of brain neural activity is achieved through the non-thermal effects of ultrashortwave, which refers to ultrashortwave with a frequency of 27.12MHz ± 0.6%, a wavelength of 11.06 nm, and a power of 1.6 ± 0.72 W. This application breaks through the traditional technical prejudice that high-frequency electric fields are unsuitable for the central nervous system, proving that non-thermal ultrashortwave can be safely used for brain neural modulation, opening up a completely new technical direction for neural modulation. With "ultrashortwave + application scenario" as its core protection element, it provides fundamental patent support for research on the treatment of various central nervous system diseases such as Parkinson's disease, stroke, depression, and Alzheimer's disease, possessing extremely high core patent value and broad clinical translation prospects.

The present application relates to the field of medicine, and particularly relates to a liposome loaded with phagolysosomal peptide, a preparation method and application thereof, so as to provide a drug for treating pancreatitis, and meanwhile improve the bioavailability of the drug. The liposome loaded with phagolysosomal peptide comprises phagolysosomal peptide and a shell coated on the periphery of the phagolysosomal peptide, the shell comprises an inner layer and an outer layer, the shell component is distearoyl phosphatidyl ethanolamine-polyethylene glycol, and there is a selenium-selenium bond between the inner layer and the outer layer. The inventor of the present application first discloses the direct effect and mechanism of the phagolysosomal peptide on the damaged pancreas of SAP, and the prepared DSSM@TN liposome can inhibit P2X7-induced mitochondrial damage, accumulation of ROS and expression of NLRP3, improve the bioavailability of the phagolysosomal peptide, significantly enhance the efficacy of the phagolysosomal peptide, and further improve the potential of the phagolysosomal peptide in preventing and treating SAP in the clinic. The DSSM@TN liposome can be used as a drug for treating pancreatitis, and meanwhile provides a new direction for the treatment research of pancreatitis.

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to application of NUPR1 in extracellular inhibition of protein translation. Specifically, experiments prove that NUPR1 can be directly combined with ribosome outside cells to compete for mRNA binding sites and induce the conformational change of the ribosome, so that powerful inhibition on in-vitro protein translation is realized; and meanwhile, based on the conservative property of a ribosome mRNA channel, the effect is speculated to be suitable for other eukaryotic cell lines. The findings not only reveal the specific action mechanism of the NUPR1 in protein translation regulation, but also provide key theoretical basis and experimental basis for subsequent development of short-peptide protein translation inhibitors (such as short peptides simulating NUPR1 binding structural domains) based on the NUPR1, and have important significance on targeted therapy research of related diseases.

The invention relates to the technical field of animal model establishment, and discloses a method for establishing an animal model with abnormal skin pigments. The construction method comprises the steps of: providing an animal having skin without hair coverage and a drug solution containing 1, 3-dihydroxyacetone (DHA) and a penetration enhancer; loading the medicine solution on the skin, which is not covered by hair, of the animal, and then carrying out ultraviolet radiation; and waiting for 8-16 hours to obtain the animal model with abnormal skin pigment. According to the construction method, the melanin-like synthesis and accumulation effect caused by DHA can be enhanced in a short time, the modeling time is remarkably shortened, and skin injuries such as erythema and blisters are reduced. Compared with a traditional ultraviolet radiation method, the model success rate is higher, operation is simpler and more convenient, stable and uniform chromatosis can be formed, the method is suitable for standardized evaluation and research of skin disease treatment schemes, and a more efficient animal model is provided for treatment research of skin pigment abnormality diseases.

The present invention provides a HER2-targeting nanomonoclonal antibody IDM3-59 and a preparation method and application thereof, wherein the complementary determining region CDR of the nanomonoclonal antibody includes CDR1, CDR2 and CDR3; wherein the amino acid sequences of CDR1, CDR2 and CDR3 are GSIFSTYN, LTRDGVA and KTLPLTRDWGSAD, respectively. The nanomonoclonal antibody provided by the present invention has high specificity for human HER2 protein, strong affinity, and is easy to produce and has high stability, and is suitable for various cancer diagnosis and treatment studies targeting HER2.

According to the construction method and application of the acute otitis media Bama miniature pig model, the acute otitis media Bama miniature pig model which is easy to operate, high in success rate, typical in symptom and high in postoperative survival rate is established, and the acute otitis media Bama miniature pig model is used for research on acute otitis media pathogenesis and treatment schemes. And a new way is provided for the treatment research of acute otitis media.

The invention discloses a fluorescent probe and a preparation method and application thereof.The structural formula of the fluorescent probe is shown in the formula I. The preparation method comprises the steps that a raw material A and a raw material B serve as reaction raw materials and are added into an organic solvent, then a catalyst tetrabutylammonium bromide is added, a condensation reaction is carried out under the sealing condition at the temperature of 60-80 DEG C, cyclization is carried out, and the fluorescent probe is obtained. A series of fluorescent probes are synthesized, high sensitivity and rapid response detection of A beta are realized by using a twisted intramolecular charge transfer mechanism, and meanwhile, the probe is ensured to have good biocompatibility so as to meet the requirements of early diagnosis and treatment research of Alzheimer's disease. # imgabs0 #

The invention discloses a carya illinoensis black spot pathogenic bacterium and application thereof.The carya illinoensis black spot pathogenic bacterium can infect carya illinoensis to generate the black spot, has high pathogenicity, can be used for research on the carya illinoensis black spot, and is beneficial to research on prevention and treatment of the carya illinoensis black spot; the method can be used for screening and developing the carya illinoensis black spot disease prevention and treatment agent.